收藏切换
Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer
收藏切换
Lei NIU, Chengyu HUO, Zongzhi LIU
World Clinical Drug | 2026, 47(2) : 149 - 156
Less
收藏切换
World Clinical Drug | 2026, 47(2): 149-156
• Article •
Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer
Full
Lei NIU, Chengyu HUO, Zongzhi LIU
Affiliations
  • Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China
Published: 2026-02-10 doi: 10.13683/j.wph.2026.02.006
Outline
收藏切换
Objective

To investigate the impact of osimertinib targeted therapy on short-term efficacy in patients with epidermal growth factor receptor(EGFR)-mutated advanced non-small cell lung cancer(NSCLC).

Methods

A retrospective analysis was conducted on clinical data from 134 patients with EGFR-mutated advanced NSCLC admitted to our hospital from December 2023 to March 2025. Patients were divided into a control group(pemetrexed+cisplatin chemotherapy, n=64) and a combination group(osimertinib+pemetrexed+cisplatin chemotherapy, n=70) according to the actual treatment received. The short-term efficacy, serum tumor markers [carcinoembryonic antigen(CEA), cytokeratin 19 fragment antige(Cyfra) 21-1, neuron-specific enolase(NSE)], angiogenesis indicators[vascular endothelial growth factor(VEGF), matrix metalloproteinase(MMP)-9, cytosolic thymidine kinase(TK)1], and adverse reactions were compared between the two groups. Based on the Kaplan-Meier survival curve, the overall survival(OS) and progression-free survival(PFS) were compared.

Results

After treatment, the disease control rate(DCR) in the combination group was higher than that in the control group(90.00% vs. 75.00%, P<0.05). Serum levels of CEA, Cyfra21-1, NSE, VEGF, MMP-9, and TK1 in the combination group were significantly lower than those in the control group(P<0.05). There was no statistically significant difference in adverse reactions between the two groups(P>0.05). The survival functions of OS and PFS in the combination group were better than those in the control group(χ2=4.720, 5.014, P=0.030, 0.025).

Conclusion

Osimertinib targeted therapy for patients with advanced NSCLC with EGFR mutations can significantly reduce serum tumor markers and angiogenesis indicators, improves DCR, OS rate, and prolong the median PFS period, and does not significantly increase the adverse reactions.

non-small cell lung cancer  /  epidermal growth factor receptor  /  osimertinib  /  pemetrexed  /  cisplatin  /  prognosis
牛磊, 霍承瑜, 刘宗志. 奥希替尼靶向治疗对EGFR突变晚期非小细胞肺癌患者血清肿瘤标志物及预后的影响. 世界临床药物, 2026 , 47 (2) : 149 -156 . DOI: 10.13683/j.wph.2026.02.006
Lei NIU, Chengyu HUO, Zongzhi LIU. Impact of osimertinib-targeted therapy on serum tumor markers and prognosis in patients with EGFR-mutated advanced non-small cell lung cancer[J]. World Clinical Drug, 2026 , 47 (2) : 149 -156 . DOI: 10.13683/j.wph.2026.02.006
Year 2026 volume 47 Issue 2
58
15
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.02.006
  • Receive Date:2025-09-28
  • Online Date:2026-11-05
  • Published:2026-02-10
Article Data
Affiliations
History
  • Received:2025-09-28
Affiliations
    Department of Thoracic Surgery, Civil Aviation General Hospital, Beijing 100123, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.02.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT